This content is machine translated Focus on diabetes and heart New studies and new recommendations Study data in recent years have highlighted the enormous extent to which type 2 diabetes mellitus (T2D) promotes the development of cardiovascular disease. In addition, it became clear that certain…
View Post 3 min This content is machine translated Heart failure SGLT-2 inhibitors – great therapeutic potential in HFrEF patients. In addition to the SGLT-2 inhibitor dapagliflozin, which was also approved by Swissmedic last July for the treatment of heart failure (HFrEF) in non-diabetics, another member of this drug class,…
View Post 3 min This content is machine translated Type 2 diabetes: insulin therapy - quo vadis? Basic insulin with once-weekly injection convinces An ultra-long-acting insulin analogue that only needs to be injected once a week is currently in development. The results of the clinical studies to date are promising. Insulin Icodec has…
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 1: SGED Recommendations The digital and CME-certified continuing education series “Dia-Month Club” on type 2 diabetes started on April 30.Our expert, Prof. Roger Lehmann (University Hospital Zurich), explains in the first module the… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 3: LDL cholesterol On June 25, the third module of the Dia-Month Club took place, focusing on an often underestimated risk factor, LDL cholesterol. Our expert, Prof. Isabella Sudano (University Hospital Zurich), presented… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 4: Heart In the fourth module of the Dia-Month Club on September 3, Prof. Christian Müller (University Hospital Basel) used current data to show how modern diabetes management decisively reduces the patient’s… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 5: Kidney On October 26, the fifth module of the Dia-Month Club was held on the topic of kidneys. Our expert, PD Dr. Michael Mayr (University Hospital Basel), explained the practical guardrails… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 6: Consequential diseases On November 18, the sixth module of the Dia-Month Club was held on the topic of secondary diseases of type 2 diabetes. Our expert, Dr. Thanh-Truc Ngô Bá (St. Claraspital,… CME-Test
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 7: Digital Tools On December 9, the seventh and final module of the 2021 Dia-Month Club was held on the topic of digital tools. Our expert, Prof. Roger Lehmann (University Hospital Zurich), explained… CME-Test
View Post 3 min This content is machine translated Advanced pancreatic cancer First-line therapies in the Real Life Check Currently, gemcitabine plus Nab-paclitaxel and FOLFIRINOX are considered standard first-line therapies for advanced pancreatic cancer. So far, there is no direct comparison of these options. An analysis of the German…
View Post 5 min This content is machine translated Type 2 diabetes GLP-1 receptor agonists reduce multiple cardiovascular risk factors In addition to improving glycemic control, GLP-1 receptor agonists have proven additional cardiovascular benefits. Large endpoint studies have demonstrated reductions in myocardial infarction and stroke rates and cardiovascular mortality. Another…
